We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




High-Dose Inhaled Nitric Oxide Emerges as Promising Antimicrobial Therapy

By HospiMedica International staff writers
Posted on 03 Feb 2026

Excessive antibiotic use has accelerated the emergence of bacterial resistance to standard therapies, fueling a global health crisis projected to cause more than 10 million deaths annually by 2050. More...

Among the most concerning pathogens, multidrug-resistant Pseudomonas aeruginosa accounts for approximately 20% of hospital-acquired pneumonia cases and is associated with severe disease and increased mortality. To address this challenge, investigators now report that high-dose inhaled nitric oxide demonstrates antimicrobial activity in preclinical models and was safe and feasible in early human exposure studies.

A research team at Mass General Brigham (Boston, MA, USA) investigated whether brief exposures to high concentrations of inhaled nitric oxide (iNO), a therapeutic gas with established use in critical care, could exert direct antipseudomonal effects while remaining tolerable for patients. In vitro experiments first showed dose-dependent killing of Pseudomonas aeruginosa using nitric oxide–releasing compounds. The team then tested the approach in a pig model of experimental pneumonia, where treatment with high-dose iNO at 300 parts per million significantly reduced bacterial burden compared with untreated controls and was associated with improved oxygenation and other indicators of lung infection.

Feasibility and safety were then assessed in humans through repeated exposure to high-dose inhaled nitric oxide. The investigators evaluated 10 healthy volunteers and two critically ill patients with multidrug-resistant bacterial infections, finding that treatment was well tolerated with no serious safety concerns. A retrospective analysis of patients who received high-dose inhaled nitric oxide in clinical settings, primarily during the COVID-19 pandemic, further supported its safety profile. The findings were published in Science Translational Medicine.

“These results suggest a promising strategy that could complement existing treatments. However, rigorous clinical trials are essential before this approach can be considered for routine clinical use,” said senior author Lorenzo Berra, MD, Mass General Brigham Department of Anesthesia, Critical Care and Pain Medicine: 

Related Links
Mass General Brigham


Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Silver Member
X-Ray QA Device
Accu-Gold+ Touch Pro
VTE Prevention System
Flowtron ACS900
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The AI-based approach identifies lipid regions matched well with histopathology results (Photo courtesy of Hyeong Soo Nam/KAIST)

AI-Based OCT Image Analysis Identifies High-Risk Plaques in Coronary Arteries

Lipid-rich plaques inside coronary arteries are strongly associated with heart attacks and other major cardiac events. While optical coherence tomography (OCT) provides detailed images of vessel structure... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.